endopredict (Myriad Genetics)
86
Structured Review
Myriad Genetics
endopredict
Endopredict, supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict/endopredict/pm42072806-182-22-23
Average 86 stars, based on 1 article reviews
Endopredict, supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict/endopredict/pm42072806-182-22-23
Average 86 stars, based on 1 article reviews
endopredict - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Introduce:Article Title: Assessing the Performance of the PREDICT Breast Version 3.0 Prognostic Tool in Patients With Breast Cancer in the United States. Article Snippet: Background: PREDICT Breast version 3 (v3) is the latest updated prognostication tool, developed using data from approximately 35,000 women diagnosed with breast cancer between 2000 and 2018 in the United Kingdom.. Although an earlier version of PREDICT was tested in the United States, the performance of the latest version remains unknown.. This study aims to validate PREDICT Breast v3 using newly released SEER outcome data for patients with breast cancer in the United States and to address potential health disparities.Methods:A total of 615,865 female patients diagnosed with primary breast cancer between 2000 and 2018 and followed for at least 10 years were selected from the SEER database. Gene Expression:Article Title: Assessing the Performance of the PREDICT Breast Version 3.0 Prognostic Tool in Patients With Breast Cancer in the United States. Article Snippet: Background: PREDICT Breast version 3 (v3) is the latest updated prognostication tool, developed using data from approximately 35,000 women diagnosed with breast cancer between 2000 and 2018 in the United Kingdom.. Although an earlier version of PREDICT was tested in the United States, the performance of the latest version remains unknown.. This study aims to validate PREDICT Breast v3 using newly released SEER outcome data for patients with breast cancer in the United States and to address potential health disparities.Methods:A total of 615,865 female patients diagnosed with primary breast cancer between 2000 and 2018 and followed for at least 10 years were selected from the SEER database. PAM50 Assay:Article Title: Advances in Breast Cancer Diagnostics: From Screening to Precision Medicine. Article Snippet: .. Prosigna (NanoString Technologies, Bothell, DC, USA), the PAM50-based assay generating a Risk https://doi.org/10.3390/diagnostics16081181 of Recurrence (ROR) score and intrinsic subtype classification, and Article Title: Advances in Breast Cancer Diagnostics: From Screening to Precision Medicine Article Snippet: .. Prosigna (NanoString Technologies, Bothell, DC, USA), the PAM50-based assay generating a Risk of Recurrence (ROR) score and intrinsic subtype classification, and |